Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results

Eagle Pharmaceuticals (EGRX) PT Lowered to $64 at RBC Capital

November 2, 2018 7:01 AM EDT

RBC Capital analyst Randall Stanicky lowered the price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $64.00 (from $84.00) while maintaining an Outperform rating.

Stanicky said results place a spotlight on recent pipeline setbacks and outlook.

... More

Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 7c, Revenues Miss

November 1, 2018 6:51 AM EDT

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.91, $0.07 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.23 million.

While we were disappointed in the outcome of the fulvestrant trial, we believe in the strength of the remaining products in our pipeline and... More